Latest Headlines

Latest Headlines

Analysts: CMO market will double by 2018

Thanks to a burgeoning Asian market and industry-wide cost-cutting, the CMO business will more than double in size by 2018, GBI Research says, expanding from $26 billion in 2010 to $59.9 billion.

DSM expands CMO biz with first Brazilian deal

DSM Pharmaceutical Products, the CMO wing of Royal DSM, has signed a deal to manufacture biologics for Brazil's Recepta Biopharma.

Indian PM urged to tax CMOs in excise-free zones

For the past 6 years, CMOs in certain regions of India have been able to operate without paying excise taxes on the products they produce, but one pharma group is imploring the government to put an end to the program.

CoreRx triples capacity with Florida plant

CoreRx has moved into its new 35,000-square-foot facility in Clearwater, FL, and the new lab will more than triple the CRO's daily capactiy, the company said.

Novasep pours $3.7M into French API plant

CMO Novasep is investing €3 million ($3.7 million) to expand its highly potent active pharmaceutical ingredient production, pouring the cash into its Le Mans, France, facility.

UPDATED: ScinoPharm will make API for blockbuster hopeful Qsymia

Taiwanese CMO ScinoPharm is looking to cash in on Vivus' diet drug, signing on to manufacture one of the pill's APIs.

Indian regulators shutter 12 drug plants over enviro concerns

Regulators in the Indian state of Andhra Pradesh are shutting down 12 API-producing plants there, saying the manufacturers ran afoul of local environmental regulations.

Indonesia to produce bird flu vaccine in 2013

In an effort to cut costs, Indonesia's PT Bio Farma will start producing a vaccine for the bird flu virus by 2013.

CMO execs reflect on changing manufacturing front

As a  Genetic Engineering & Biotechnology News  story reveals, they are embracing strategic partnerships and adding capabilities to their arsenal to ensure long-term success.

Group tackles dengue vaccine pricing

Production of a dengue vaccine could cost mere pocket change, according to an economic analysis completed by the Dengue Vaccine Initiative. Producing a tetravalent dengue vaccine could cost as little as 20 cents per dose, with an annual production level of 60 million doses packaged in 10-dose vials.